Mdxhealth Sa (MDXH) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Mdxhealth Sa (MDXH) stock forecast summary
On Oct. 16, 2026, MDXH is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5172 stocks scored that day.
Mdxhealth Sa is a small-cap company with a market capitalization of $58M. It ranks number 22 by market capitalization among the 29 Services-Medical Laboratories issuers in our coverage with a current forecast.
For MDXH, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 38.0%, measured on 217 forecast dates between 2025-04-04 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -3.0%, measured on 260 forecast dates between 2025-04-04 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, MDXH included.
Follow MDXH freeMDXH price chart and AI forecast
How MDXH ranks among 5172 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Mdxhealth Sa (MDXH) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Medical Laboratories peers listed below that report each metric.
Valuation & Market
| Metric | MDXH | Rank |
|---|---|---|
| Market Cap | $58M | 22/29 |
Dividend & Shareholder Information
| Metric | MDXH | Rank |
|---|---|---|
| Shares Outstanding | 95M | – |
Balance Sheet Highlights (USD millions)
| Total Liabilities | $142M |
MDXH quarterly financials and insider trading
Mdxhealth Sa (MDXH) industry peers
Companies classified under the same SEC industry code as Mdxhealth Sa (Services-Medical Laboratories): 30 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| MDXH Mdxhealth Sa | ▶ | $58M |
| NTRA Natera, Inc. | ▲ | $56.71B |
| DGX Quest Diagnostics Inc | ▼ | $25.94B |
| LH Labcorp Holdings Inc. | ▶ | $25.79B |
| GH Guardant Health, Inc. | ▲ | $21.28B |
| CAI Caris Life Sciences, Inc. | ▲ | $8.64B |
| RDNT Radnet, Inc. | ▶ | $5.41B |
| GRAL Grail, Inc. | ▲ | $5.26B |
| BLLN Billiontoone, Inc. | ▲ | $4.63B |
| VCYT Veracyte, Inc. | ▲ | $3.47B |
| CDNA Caredx, Inc. | ▲ | $3.31B |
| CELC Celcuity Inc. | ▲ | $2.77B |
| FTRE Fortrea Holdings Inc. | ▶ | $2.14B |
| PSNL Personalis, Inc. | ▼ | $1.67B |
| FRNM Freenome, Inc. | ▶ | $1.26B |
| LMRI Lumexa Imaging Holdings, Inc. | ▶ | $1.04B |
| CSTL Castle Biosciences Inc | ▲ | $976M |
| FLGT Fulgent Genetics, Inc. | ▲ | $545M |
| BDSX Biodesix Inc | ▲ | $250M |
| XGN Exagen Inc. | ▲ | $187M |
| BNR Burning Rock Biotech Ltd | ▲ | $168M |
| SERA Sera Prognostics, Inc. | ▼ | $78M |
| CFOR Capforce Inc. | ▶ | $43M |
| AMS American Shared Hospital Services | ▼ | $9M |
| ADVB Advanced Biomed Inc. | ▶ | $7M |
| ACON Aclarion, Inc. | ▲ | $5M |
| BGLC Bionexus Gene Lab Corp | ▲ | $4M |
| LUDG Ludwig Enterprises, Inc. | ▶ | $670K |
| FCHS First Choice Healthcare Solutions, Inc. | ▶ | $260K |
| RNLXY Renalytix Plc | ▲ | N/A |
Where MDXH sits on the market map
Mdxhealth Sa (MDXH) stock news
Loading...
Mdxhealth Sa (MDXH) stock forecast FAQ
What is the Mdxhealth Sa (MDXH) stock forecast?
On Oct. 16, 2026, MDXH is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5172 stocks scored that day.
How accurate are Mdxhealth Sa stock predictions?
For MDXH, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 38.0%, measured on 217 forecast dates between 2025-04-04 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -3.0%, measured on 260 forecast dates between 2025-04-04 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Mdxhealth Sa forecasts updated?
Mdxhealth Sa forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Mdxhealth Sa's industry peers?
30 issuers in our coverage, MDXH included, share the SEC industry code Services-Medical Laboratories. The largest are: Natera, Inc. (NTRA), Quest Diagnostics Inc (DGX), Labcorp Holdings Inc. (LH), Guardant Health, Inc. (GH), Caris Life Sciences, Inc. (CAI), Radnet, Inc. (RDNT).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.